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Poster Session-II 129during therapy in patients with cGVHD, and correlating cell num-
bers with response.
Methods:We studied 25 adult pts with histories of hematological
malignancies who developed cGVHD after allogeneic, HLA-
matched HPCT. At the time of ECP initiation, pts were either de-
pendent upon corticosteroids for control of cGvHD (21 pts), or ste-
roid-intolerant (4 pts). A good response was defined as having. 50%
reduction in the corticosteroid dose within 4 months of starting
ECP, with improved or stable lesions on skin and other sites. For ste-
roid-intolerant pts, improvement in skin condition was used to iden-
tify responders. PBMCs were analyzed before ECP began and every
2 months during ECP therapy. The numbers of plasmacytoid DCs
(pDC, Lin-CD1231CD11c-HLA-DR1), myeloid DCs (mDC,
Lin-CD123-CD11c1HLA-DR1), and CD41 and CD81 T-cells
in blood were determined by flow cytometry.
Results:Themedian number of ECP treatments was 26 (range 2–
68). Fourteen pts (56%) had good response, and 11 were non-re-
sponders. Responders had an estimated 2-yr survival of 88% after
starting ECP, vs 18% for non-responders (p 5 0.004). Responders
had higher baseline numbers of pDCs (average 5.8 vs. 0.6 cells/
mcL, p 5 0.025) and mDCs (average 15 vs. 3.8 cells/mcL, p 5
0.01) compared with non-responders. Baseline CD41 T-cell num-
bers were higher in responders compared with non-responders (av-
erage 623 vs. 178 cells/mcL, p 5 0.005), as were CD81 T-cell
numbers (712 vs. 251 cells/mcL, p 5 0.047). There was no correla-
tion between incidence of infection and numbers of T-cells or DCs,
or response to ECP. Contrary to the original hypothesis, there were
no consistent changes in the numbers of circulating DCs and T-cells
among responders over a 12-month period.
Conclusion:Our results demonstrate that higher numbers of cir-
culating DCs and T-cells predict response to ECP in pts with
cGVHD. Response to ECP was significantly associated with im-
proved survival in univariate and multivariate analyses (p\0.03).
Our findings support a newer model for the mechanism of response
to ECP therapy, involving interactions between donor-derived DCs
and donor T-cells.359
POST-TRANSPLANT IMMUNOTHERAPY FOR PEDIATRIC ALL
Qin, H., Capitini, C.M., Wayne, A.S., Fry, T.J. National Institutes of
Health, Bethesda, MD
Background: Pediatric Acute Lymphoblastic Leukemia (ALL) is
the most common childhood malignancy. Despite substantial ad-
vancements in upfront therapy, management of patients with relapse
remains one of the difficult challenges in pediatric oncology. Alloge-
neic transplantation can be curative for relapsing ALL, in part due to
a graft versus leukemia effect. The ability to develop these ap-
proaches has been limited by lack of suitable pre-clinical models of
pediatric ALL. Thus, we sought to develop a murine model of pedi-
atric ALL to explore post-transplant immunotherapeutic strategies.
Methods: E2A-PBX1 is a translocation that occurs in approxi-
mately 5% of pediatric ALL. We utilized leukemia cells from
E2A-PBX1 transgenic/CD3epsilon -/- mice that spontaneously de-
velop precursor B cell ALL (Bijl J. et al. Gene & Development
19:224–233, 2005) to establish a transplantable ALL model.
Results: After conditioning in stem cell media, E2a-PBX1 cells
could be cultured in vitro and generated leukemia consistently.
The phenotype and pattern of dissemination is analogous to pediat-
ric pre-B ALL. Immunization with dendritic cells (DC) pulsed with
irradiated E2A-PBX1 cells protected against the development of leu-
kemia.We next sought to establish a bonemarrow transplant (BMT)
model of minimal residual disease (MRD). Injection of E2A-PBX1
cells prior to lethal irradiation and injection of minor MHC antigen
mismatched BMT resulted in the development of leukemia in two to
four weeks post BMT thus mimicking a model of minimal residual
disease. Ongoing experiments are exploring the ability to treat
MRD with DC vaccination, adoptive T cell transfer, drugs or com-
bination therapy.
Conclusions:We have established a transplantable model of pre-
B cell ALL that mimics pediatric ALL, can be prevented by vaccines,
and develop following anMRD state in allogeneic BMT.This model
provides an excellent system to test strategies to diminish relapse fol-
lowing allogeneic transplantation for pediatric ALL.360
DAY7 TNFR1 LEVELS FOLLOWING REDUCED INTENSITY ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT (HCT) PREDICT FOR ACUTE
GVHD
Kitko, C.L., Mineishi, S., Braun, T., Choi, S.W., Jones, D., Harris, A.,
Khaled, Y., Krijanovski, O., Paczesny, S., Peres, E., Yanik, G.,
Whitfield, J., Ferrara, J.L., Levine, J.E. University of Michigan, Ann
Arbor, MI
Tumor necrosis factor-a (TNF) is significant in the pathogenesis
of GVHD. We have previously shown that early rises in soluble
TNF receptor 1 (TNFR1) levels measured on day 7 following mye-
loablative (MA) allogeneic HCT predict the development of GVHD
and TRM. In the setting of reduced intensity conditioning (RIC)
GVHD rates are similar to MA even though GVHD onset is often
delayed. We therefore hypothesized that TNFR1 levels on day 7
would correlate with GVHD after RIC. TNFR1 levels were mea-
sured on day 7 post-HCT in 156 pts (median age 56.6y, range 7–
71y) who underwent RIC HCT between 2000 to 2008. Pre-HCT
conditioning was Fludarabine (125–180 mg/m2) and Busulfan (6.4–
8.0 mg/kg) 6 total lymphoid irradiation (2–4 Gy) in 142 pts, with
minor variations in 14 pts, including 6 that received ATG. GVHD
prophylaxis was tacrolimus (day -3 to 180) and short-course metho-
trexate (5 mg/m2 on day 1,3,6,11 in 99 pts) or mycophenolate (day 0–
28 in 57 pts). There were 47 related donor (RD) pts (30%), 109 un-
related donor (URD) pts (70%) and 34 pts received single antigen
mismatched HCT (6 RD, 28 URD). The incidence of GVHD 2–4
was 49% in URD and 39% in RD. The median day of GVHD onset
was 32d (range 6–162d); 56d in the RD and 30d in the URD (p 5
0.02). The logarithm of TNFR1 levels was used for the analysis in
order to normalize right-skewed values. Regression analysis revealed
that a doubling in day 7 TNFR1 levels increased the risk of GVHD
2–4 by 1.36 times (p5 0.007), however, the risk appeared to be pri-
marily in the URD pts [Table 1]. Consistent with this observation,
the median day 7 TNFR1 level was significantly higher in pts devel-
oping GVHD 2–4 after URD (11.4 vs 11.0, p 5 0.01), but not after
RD RIC HCT (11.3 vs 11.1, p 5 0.38). Using the median TNFR1
level in URD HCT as a threshold, we found that pts with day 7
TNFR1 levels above the median were more likely to develop
GVHD 2–4 (p 5 0.008). This correlation remained significant
(p 5 0.01) after adjustment for pt age, gender and HLA match.
We conclude that for pts undergoing RIC HCT, a higher day 7
TNFR1 level correlates with incidence of GVHD 2–4. This effect
of TNFR1 on GVHD was strongest in the URD setting where do-
nor response to host alloantigens is more robust and GVHD de-
velops more quickly. The informative value of a day 7 TNFR1
level decreases in RD pts who develop GVHD a median of 7 weeks
later, suggesting that GVHD in the RD RIC setting is not strongly
dependent on conditioning induced TNF release.
Association of TNFR1 with Risk of GVHD 2-4
Donor Risk Ratio* p-valueOverall (n5156) 1.36 0.007
RD (n547) 1.22 0.44
URD (n5109) 1.42 0.006*Risk Ratio is for a doubling of TNFR1 levels361
DENILEUKIN DIFITOX (ONTAK) FOR THE TREATMENT OF ADVANCED
STEROID-REFRACTORY GVHD: SINGLE INSTITUTION EXPERIENCE
Abar, F.1, Leis, J.F.2, Jacoby, C.E.1, Mishra, M.1, Bubalo, J.S.1,
Curtin, P.T.3, Hayes-Lattin, B.L.1, Meyers, G.1, Slater, S.E.1,
Subbiah, N.1, Maziarz, R.T.1 1OHSU; 2Mayo; 3UCSD
Steroid Resistant (SR)-GVHD is associated with high mortality
when in encountered in allogeneic stem cell transplantation . Deni-
leukin Diftitox (DD), a recombinant fusion protein composed of the
cytocidal A chain of Diphtheria toxin and binding portion of IL-2,
has potent activity against activated CD251 T cells important in
the etiology of GVHD. It has been reported that DDmay have ther-
apeutic activity for the treatment of SR-GHVD (Ho et al, BLOOD
2004). This approach was adopted within our institution for
130 Poster Session-IISR-GVHD, defined as lack of response or disease progression after
at least 7 days of treatment with methylprednisolone at 2 mg/kg. Be-
tween 3/2003 and 6/2008, 20 patients with advanced SR-GVHD fol-
lowing allogeneic transplantation were treated with DD at OHSU, 7
afterMRD and 13 after URD (six matched, one A antigenmismatch,
and six allele mismatch) .GVHD prophylaxis consisted of cyclo-
psporine, methotrexate, and steroid (19) or cyclosporine plus
MMF (1). Nineteen patients developed acute SR-GVHD overall
grade III (7) and IV (12) while one patient developed chronic exten-
sive SR-GVHD. Twelve patients received DD as first salvage ther-
apy while 8 patients were treated with other agents prior to DD (6
had one and 2 had two prior salvage therapies including MMF and
Etanercept). Planned treatment was DD at a dose of 600 mcg
(9mcg/kg) on days 1, 3, 5, 15, 17, and 19.Median days toDD therapy
after stem cell transplant was 38.Ten patients showed response (4CR
and 6 PR defined as at least a one overall grade improvement), six
were non responders, and four patients died before completion of
treatment. One patient remains alive. Causes of death included
GVHD (8), opportunistic infection (5), respiratory failure (2), trans-
plant-associated microangiopathy (2), ICH (1), and relapse (1). Me-
dian survival for the entire group was 30.5 days from the onset of DD
(4–18391) with median survival of 116 days for patients who re-
ceived all 6 doses of DD. Despite measurable responses in 50% of
patients, no survival benefit was observed. Profound immune sup-
pression was significant among responders, contributing to opportu-
nistic infection and death. Thus, DD may be most beneficial if used
earlier in the course or in lower grade aGVHD. Responses can be
achieved in advanced SR-GVHDwithDDbut novel approaches still
remain the research target for these patients given poor overall
survival .362
EVALUATION OF ALLOIMMUNE RESPONSES IN HUMANIZED NOD/SCID/
IL2RGNULL MICE FOLLOWING HUMAN CD341 STEM CELL TRANSPLAN-
TATION
Hartwig, U.F.1, Hemmerling, J.1, Hoffmann, J.1, Andre, M.C.2,
Handgretinger, R.2, Huber, C.1, Herr, W.1, Meyer, R.G.1 1Johannes
Gutenberg-University School of Medicine,Mainz, Germany; 2Eberhard--
Karls University School of Medicine, Tuebingen, Germany
Immunodeficient NOD/SCID/IL2Rg (yc)null mice can be effi-
ciently used to establish human lymphohematopoiesis or lymphohe-
matological neoplasia in a murine environment. Thus, upon
engraftment of human CD341 hematopoietic stem cells (HSC) or
acute leukemia cells and allogeneic donor lymphocyte infusions
these mice might become a powerful tool to provide an allogeneic
HSCT model for investigating human graft-vs-host (GvH)- and
graft-vs-leukemia (GvL)-immunity in vivo. In the current study,
we engrafted NOD/SCID/ycnull mice with human CD341 HSC to
provide a model for analyzing the role of patient-derived antigen
presenting cells for the induction of GvH- and GvL-reactivity and
to evaluate reactivity to human alloantigens of ex vivo engineered
T cell allografts for improved immunotherapy. Following reconsti-
tution of busulfan conditioned neonatal or (300 cGy) irradiated adult
NOD/SCID/ycnull recipients with 1  105 to 1  106 purified
CD341 adult HSC and weekly i.v. injections of Fc-IL7, human
CD451 PBMNC were detected as early as early as 30 or 60 days
(d) post reconstitution of newborn and adult mice, respectively. After
120d, T-, B-, and NK-cells, as well as monocytes and dendritic cells
(DCs) were found in spleen (SPL) and bonemarrow of both newborn
and adult recipients by flow cytometry and immunhistological stud-
ies in e.g. SPL and skin. However, as reconstitution of newborns re-
sulted in thymopoiesis of human CD31 cells and better lympho- and
myelopoiesis as compared to adult mice, further studies were per-
formed in HSC engrafted newborn recipients. Functional analyses
of lymphocytes grown in humanized NOD/SCID/ycnull mice re-
vealed that human CD31 T cells isolated from SPL and challenged
ex vivo with i) murineNOD/SCID/ycnull derivedDCs, ii) HLA-mis-
matched DCs or iii) HSC donor derived (autologous) DCs elicited
alloresponses to human but not murine alloantigens(s). These results
and further studies on ex vivo examined allo- and xenoimmunity of
naı¨ve HLA-matched and HLA-mismatched CD81 T cells trans-
ferred into HSC engrafted NOD/SCID/ycnull recipients will be pre-
sented to demonstrate T cell alloimmune responses in humanized
mice and to show that our model can be used to evaluate residualGvH reactivity of CD81 donor T cells in HLA- matched or haploi-
dentical settings. Finally, these studies should help to elucidate the
impact of xenoreactivity on the induction of GvH immunity by hu-
man T cells in humanized mice.363
PROPHYLACTIC ADMINISTRATION OF EX VIVO CO-STIMULATED DONOR
LYMPHOCYTE INFUSION (DLI) FROM RELATED AND UNRELATED
DONORS AFTER REDUCED INTENSITY CONDITIONING FOR HIGH RISK
HEMATOLOGIC MALIGNANCIES
Goldstein, S.C., Levine, B., Smith, J., Hinkle, J., Luger, S., Perl, A.,
Loren, A., Frey, N., Stadtmauer, E., Porter, D.L., June, C.H. University
of Pennsylvania, Philadelphia, PA
Enhancing the graft versus tumor (GvT) effect without graft ver-
sus host disease (GvHD) is critical to the success of reduced intensity
(RIC) strategies for allogeneic transplantation. Despite establishing
donor lymphohematopoiesis, relapse rates remain high. Standard
DLI given at relapse or prophylactically to enhance donor chimerism
has met with limited success in improving transplant outcomes. Co-
stimulation of donor T-cells, using anti-CD3/CD28 coated beads to
serve as artificial APCs, may reverse functional T cell tolerance,
thereby restoring immune responsiveness and potentiate GVT. Un-
like standardDLI, ex vivo co-stimulationmay enhanceT cell activity
by removing and activating T cells outside of a tumor-induced im-
munosuppressive milieu. We report the preliminary results of a fea-
sibility trial of ex vivo co-stimulated DLI from sibling and unrelated
donors given ‘prophylactically’ at 4 and 6 months after RIC alloge-
neic transplantation for patients (pts) with high-risk hematologic
malignancy.
Methods: 15 pts have undergone RICwith alemtuzumab, Fludar-
abine,Busulfan with peripheral blood stem cell transplantation
(PBSCT) and planned activated DLI (pADLI) at 4 months (1 
107 CD31/kg) and 6 months (1  108 CD31/kg) post-transplant
in the absence of GvHD or relapse. All pts received tacrolimus and
methotrexate as GvHD prophylaxis.
Results: 8 pts (AML, n5 6; ALLCR1 n5 2) received grafts from
HLA-identical sibling donors, 7 (AML n5 5;MDS n5 1; ALL, n5
1) from matched unrelated donors. Donor hematopoiesis was estab-
lished in all patients. Of the 11 infusions given to date, there has been
no infusion-related toxicity, confirming the safety and feasibility of
this strategy. 8 pts have received the first of 2 planned infusions of
pADLI. Of the remaining 7 pts, 4 infusions are upcoming, 1 was pre-
cluded by early relapse, and 2 were precluded by early NRRM. Of
the 8 pts who received their initial pADLI#1, 3 have received a second
infusion. 5 pts did not receive pADLI#2 because of relapse (n 5 3),
GvHD (n5 1), and transient uveitis in the absence ofGvHD (n5 1).
Overall incidence of acute GvHD (aGvHD) has been low; 1 pt devel-
oped aGvHD prior to pADLI#1, and 1 pt developed aGvHD after
pADLI #1. No patient has developed chronic GvHD.
Conclusion: Preliminary results of this trial demonstrates that
RIC with PBSCT followed by ex vivo costimulated pADLI for
poor prognosis hematologic malignancies is safe and feasible with
potential for enhancing GvT without increasing GvHD.364
CLINICAL EXPANSION OF CORD BLOOD DERIVED T CELLS FOR USE AS
DONOR LYMPHOCYTE INFUSION AFTER CORD BLOOD TRANSPLANTA-
TION
Okas, M.1,2, Gertow, J.1,2, Uzunel, M.1, Karlsson, H.1, Uzunel, M.1,
Ringden, O.1,2, Mattsson, J.1,2, Uhlin, M.1,2 1Karolinska Institutet,
Stockholm, Sweden; 2Karolinska University Hospital, Stockholm, Sweden
Background: When no HLA-identical donor is available, cord
blood transplantation (CBT) is an attractive option due to the rapid
availability of the graft and its biological properties. One of the dis-
advantages associated with CBT is lack of possibility for donor lym-
phocyte infusion (DLI) after CBT. Here we report expansion and
characterization of CD3 positive lymphocytes from CB grafts in
connection to CBT.
Material andMethods:Lymphocytes from 13 CB grafts were ex-
panded with CD3/CD28 beads and 200 IU/ml rIL2. Expanded cells
were cryopreserved in ready-to-use DLI doses. Immunophenotyp-
ing and cytokine production assay were performed on expanded
